GlaxoSmithKline
NEWS
Three months after joining forces to develop an adjuvanted vaccine for COVID-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
“We are pleased the committee recognized the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options,” said Axel Hoos, senior vice president and heat of Oncology R&D for GSK.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
JOBS
IN THE PRESS